In Vitro-In Vivo Correlations Observed with Indacaterol-Based Formulations Delivered with the Breezhaler®

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 4, 2015, Pages 268-280

  Weers, Jeffry G ^a   Clark, Andrew R ^a   Rao, Nagaraja ^a   Ung, Keith ^a   Haynes, Alfred ^a   Khindri, Sanjeev K ^b   Perry, Sheryl A ^b   Machineni, Surendra ^c   Colthorpe, Paul ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

Alberta Idealized Throat; IVIVC; PulmoSphere

Indexed keywords

ACTIVATED CARBON; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; AEROSOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG CARRIER; DRUG COMBINATION; GLYCOPYRRONIUM BROMIDE; INDAN DERIVATIVE; LACTOSE; MUSCARINIC RECEPTOR BLOCKING AGENT; POWDER; QUINOLONE DERIVATIVE;

AEROSOL; ALBERTA IDEALIZED THROAT MODEL; ANATOMIC MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRY POWDER INHALER; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PARTICLE SIZE; PEAK INSPIRATORY FLOW; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; ANATOMY AND HISTOLOGY; AUDIOVISUAL EQUIPMENT; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DRUG COMBINATION; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PHARYNX; POWDER; THERAPEUTIC EQUIVALENCE; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; GLYCOPYRROLATE; HUMANS; INDANS; LACTOSE; MODELS, ANATOMIC; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PARTICLE SIZE; PHARYNX; POWDERS; QUINOLONES; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 84930089099     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1178     Document Type: Article

References (42)

1. Olsson B, Borgström L, Lundback H, and Svensson M: Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Del. 2013; 25:355-369.
2. Delvadia RR, Longest PW, and Byron PR: In vitro tests for aerosol deposition. I. Scaling a physical model of the upper airways to predict lung deposition variation in normal humans. J Aerosol Med Pulm Drug Deliv. 2012;25:32-40.
3. Delvadia R, Hindle M, Longest PW, and Byron PR: In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2013;26:138-144.
4. Zhang Y, Gilbertson K, and Finlay WH: In vivo-in vitro comparison of deposition in three mouth-throat models with qvar and turbuhaler inhalers. J Aerosol Med. 2007; 20:227-235.
5. Ruzycki CA, Golshahi L, Vehring R, and Finlay WH: Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children. Pharm Res. 2014;31: 1525-1535.
6. Finlay WH, Ruzycki CA, Golshahi L, and Vehring R: Validating and scaling the Alberta idealized child throat. Proc Respir Drug Deliv. 2014;1:303-310.
7. Olsson B, and Bäckman P. Mouth-throat models for realistic in vitro testing-A proposal for debate. Proc Respir Drug Deliv. 2014;1:287-293.
8. Byron PR, Wei X, Delvadia RR, Longest PW, and Venitz J: Breath profiles for testing new DPI devices in development. Proc Respir Drug Deliv. 2014;1:295-302.
9. Mitchell JP, Copley M, and Solomon D: Applying the AIM concept in support of developing improved in vitro-in vivo relationships for OIPs. In: Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products (T.P. Tougas et al, eds). 2012, Springer Science, New York, NY, Chapter 12, pp. 375-400.
10. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, and Kramer B: Efficacy of a new once-Daily long-Acting inhaled beta2-Agonist indacaterol versus twice daily formoterol in COPD. Thorax. 2010;65:473-479.
11. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Igbal A, Swales J, Owen R, Higgins M, and Kramer B: Once-Daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
12. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, and Kramer B: Efficacy and safety of indacaterol 150 microg once-Daily in COPD: A double-blind, randomized, twelve-week study. BMC Pulm Med. 2010;10:11.
13. Pavkov R, Mueller S, Fiebach K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Malvi M, Dederichs J, and Rietveld I: Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26:2527-2533.
14. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, and Overend T: QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010;65:1086-1091.
15. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, and Banerji D: Efficacy and safety of once-Daily QVA149 compared with twice-Daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): A randomised, double-blind, parallel group study. Lancet Resp Med. 2013;1:51-60.
16. Colthorpe P, Voshaar T, Kieckbush T, Cuoghi E, and Jauernig J: Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-Acting muscarinic antagonist glycopyrronium. J Drug Assess. 2013;2: 11-16.
17. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble K, Clark AR, Eldon M, Elton RC, Pickford M, Hirst PH, Newman SP, and Weers JG: Improved lung delivery from a passive dry powder inhaler using an engineered Pulmo-Sphere powder. Pharm Res. 2002;19:689-695.
18. Weers JG, Ung K, Le J, Rao N, Ament B, Axford G, Maltz D, and Chan L: Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject's inhalation maneuver. J Aerosol Med Pulm Drug Del. 2013;26: 56-68.
19. Weers JG, Tarara T, Malcolmson R, and Leung D: Embedded crystals in low density particles: Formulation, manufacture, and properties. Proc Resp Drug Deliv X. 2006;1:297-304.
20. Weers JG, and Tarara TE: The PulmoSphere platform for pulmonary drug delivery. Ther Deliv. 2014;5:277-295.
21. Cazzola M, Calzetta L, Page CP, and Matera MG: Use of indacaterol for the treatment of COPD: A pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014,10: 129-137.
22. Emotte C, Heudi O, Deglave F, Bonvie A, Masson L, Picard F, Chaturvedi A, Majumdar T, Agarwal A, Woessner R, and Kretz O: Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;895-896:1-9.
23. Lock R, Price D, Khindri S, Woessner R, Weiss M, Hara H, Pylvaenaeinen I, and Kaiser G: Efficient deposition and absorption of orally inhaled indacaterol in the lungs. Eur Resp J. 2011;38:252.
24. Finlay WH, Golshahi L, Noga M, and Flores-Mir C: Choosing 3-D mouth-throat dimensions: A rational merging of medical imaging and aerodynamics. Proc Resp Drug Deliv 2010. 2010;1:185-193.
25. Stapleton KW, Guentsch E, Hoskinson MK, and Finlay WH: On the suitability of j-e turbulence modeling for aerosol deposition in the mouth and throat: A comparison with experiment. J Aerosol Sci. 2000;31:739-749.
26. Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, Fairhurst PA, Faller B, Farr D, Keller T, Fozard JR, Fullerton J, Garman S, Hatto J, Hayden C, He H, Howes C, Janus D, Jiang Z, Lewis C, Loeuillet-Ritzler F, Moser H, Reilly J, Steward A, Sykes D, Tedaldi L, Trifilieff A, Tweed M, Watson S, Wissler E, and Wyss D: The identification of indacaterol as an ultralongacting inhaled b2-Adrenoreceptor agonist. J Med Chem. 2010;53:3675-3684.
27. Chrystyn H: Effects of device design on patient compliance: Comparing the same drug in different devices. Proc RDD Europe. 2009;1:105-116.
28. Cazzola M, Bardaro F, and Stirpe E: The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2013;19:20-29.
29. Lombardi D, Cuenoud B, and Kramer SD: Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci. 2009;38:533-547.
30. Seebri Breezhaler Product Monograph, Novartis Pharmaceuticals Canada, Inc, 2014.
31. Kagan M, Dain J, Peng L, and Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012;40:1712-1722.
32. Rautakorpi P, Manner T, Ali-Melkkila T, Kaila T, Olkkola K, and Kanto J: Pharmacokinetics and oral bioavailability of glycopyrrolate in children. Pharmacol Toxicol. 1998;83: 132-134.
33. Lee SL, Adams WP, Li BV, Conner DP, Chowdhury BA. and Yu LX: In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11:414-423.
34. Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, and Chrystyn H: What the pulmonary specialist should know about the new inhalation therapies. Eur Resp J. 2011;37:1308-1331.
35. http://www.fda.gov/advisorycommittees/committeesmeeting materials/drugs/pulmonary-Allergydrugsadvisorycommittee/ucm245635.htm; accessed Jan 13, 2013.
36. Taki M, Marriot C, Zeng XM, and Martin GP: Aerodynamic deposition of combination dry powder inhaler formulations in vitro: A comparison of three impactors. Int J Pharm. 2010;388:40-51.
37. Begat P,MortonDA, Shur J, Kippax P, Staniforth JN, and Price R: The role of force control agents in high-Dose dry powder inhaler formulations. J Pharm Sci. 2009;98:2770-2783.
38. Begat P, Price R, Harris H, Morton DAV, and Staniforth JN: The influence of force control agents on the cohesiveadhesive energy balance in dry powder inhaler formulations. KONA. 2005;23:109-121.
39. Daley-Yates PT, Mehta R, Chan RH, Despa SX, and Louey MD: Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. J Aerosol Med Pulm Drug Del. 2014; 27:279-289.
40. Weers JG, Ung K, Le J, Rao N, Ament B, Axford G, Maltz D, Glusker M, and Chan L: Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject's inhalation maneuver. J Aerosol Med Pulm Drug Del. 2013;26:56-68.
41. Weers JG, Clark AR, Rao N, Ung K, Khindri SK, Perry SA, Machineni S, and Colthorpe P: Optimizing indacaterol formulations in practice: In vitro testing and PK/PD correlations. Proc Respir Drug Deliv. 2014;1:311-320.
42. Haynes A, Ament B, Heng C, Le J, Ung K, Rao R, Malcolmson R,Weers J, Pavkov R, Heuerding S, and Geller D: In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI Podhaler) using inspiratory flows from cystic fibrosis patients. Pediatr Pulmonol. 2013;48(S36):352.